



The Bulletin

September 2026

Autumn approaches with fresher mornings and evenings drawing in, leaves are starting to fall.... But which prices will also begin to fall?

The WaveData team found the biggest price fall for August was Chlortalidone Tabs 50mg 30, where as the biggest price rise was Rivastigmine Caps 3mg 28.

We have been in attendance at various events this month, including the Healthcare Distribution Association (HDA UK) Supply Chain Resilience Group. The creation a Single National Formulary (SNF) for England was back as the agenda and let to some interesting discussions.

We hope you enjoy this issue of the Bulletin, and please do follow us on Linked In for more news and commentary.

Jackie Moss

Editor

WAVEDATA'S PICK OF THIS MONTH'S TOP NEWS STORIES

- Ramipril - UK latest shortage
- Complaints of pharmacists covering braille on medication
- Pricewatch UK - Rivastigmine Rises Dominate UK Increases In August
- Britain's 'overprescribing epidemic' sees 1,000 elderly people a day to A&E
- UK - first country to launch CSL's flu shot Aujemflu
- Lupin targets \$500 million biosimilar revenue in five years
- Charles Joynson, WaveData MD, asks 'Promethazine Hydrochloride Tabs 10mg 56, is the price on the rise again?'
- Boehringer launches hub for patient experience data
- UK and Singapore launch negotiations for new agreement
- WaveData Top Ten Branded Product Searches
- WaveData Top Ten Generic Product Searches
- Future Industry Events

Ramipril - UK latest shortage

Common blood pressure medicine ramipril still faces a shortage across the UK, with supply limited until at least the end of October 2026.

Patients across the UK taking the medication are being urged to check their prescriptions early. Health officials confirm that a widespread supply shortage is expected to persist until at least the end of next month. Patients are being urged to "speak to their pharmacy team" if they are facing difficulties.

To manage the supply crunch, the government has active emergency measures, including a Serious Shortage Protocol (SSP087) specifically targeting Ramipril 1.25mg capsules. Under this protocol, pharmacists are legally authorised to ration the medication, limiting patients to a maximum of one month's supply at a time.

Source: The Mirror



Complaints of pharmacists covering braille on medication

Sight loss charity RNIB have told the C+D it has received reports from "many" patients who say they are struggling to identify their medicines due to the braille being covered by labels. Healthwatch this month highlighted the issue in a [report](#) on the challenges people with sight loss face accessing healthcare.

The NHS watchdog concluded that these patients are "still not reliably receiving accessible care", and said pharmacies covering braille with labels was a theme that "emerged repeatedly" in feedback from patients.

The RNIB estimates that approximately 1.9 million people in England live with significant sight loss.

The charity's policy lead on accessibility Khadija Raza said pharmacists covering braille on medicine packets could have "serious consequences" for patients' health if they are not able to follow the correct dosage.

Source: Chemist & Druggist



Pricewatch UK - Rivastigmine Rises Dominate UK Increases In August

Multiple presentations of rivastigmine capsules saw their UK trade prices more than double in August, according to the latest figures from WaveData.

Rivastigmine saw sharp price rises in the UK in August, according to the latest figures from market researcher WaveData.

Based on UK generic trade prices to independent pharmacists, WaveData calculated that multiple presentations of the dementia treatment saw their average price more than double last month, with different strengths of the product accounting for three of the eight top positions in our Biggest Risers table as a result.

“We started seeing pricing for this dementia medication increasing towards the later part of August,” WaveData commented, also noting that the 6mg strength – which did not feature among our Biggest Risers – “fell just short of our table with an average increase of 141%” to £5.08 (\$6.88).

Source: Generics Bulletin

GENERICS BULLETIN
CITELINE COMMERCIAL

Britain's 'overprescribing epidemic' sees 1,000 elderly people a day to A&E

Nearly eight million people across the UK are now consuming five or more prescription medicines every day.

NHS data analysis shows that up to 1,000 elderly people each day require emergency hospital treatment after suffering a preventable adverse response to their medication.

Roughly 2.2 million individuals are taking 10 or more pills daily.

The threshold of five concurrent medicines, known clinically as "polypharmacy," marks the point where the danger of harmful side-effects rises sharply, particularly among frail patients with existing mobility difficulties

Source: GBN

GBN
BRITAIN'S NEWS CHANNEL

UK - first country to launch CSL's flu shot Aujemflu

An adjuvanted, trivalent influenza vaccine developed by CSL Seqirus and recently approved in the UK, Aujemflu, will be deployed ahead of the 2027/28 flu season under an agreement with the government.

Aujemflu (aTIVc/allVc) – which was approved for use in people aged 50 and over by the MHRA in June – is the first flu shot to combine three approaches to enhancing protection for older adults in a single vaccine, i.e., the use of an adjuvant (MF59), cell-based manufacturing, and a higher-dose formulation.

Under the terms of the new agreement, the NHS will be able to use Aujemflu for seasonal flu prevention for adults aged 65 years and over, as well as for at-risk adults aged 50 to 64 who are more vulnerable to the complications of the infection. Aujemflu was added to the flu vaccine recommendations by the Joint Committee on Vaccination and Immunisation (JCVI) in July.

Source: Pharmaphorum



Lupin targets \$500 million biosimilar revenue in five years

Indian drug maker Lupin (BOM: 500257) is stepping up its biosimilars business, targeting revenue of nearly \$500 million over the next five years as it expands manufacturing capacity and builds a portfolio across major global markets.

The push follows the company's first US Food and Drug Administration approval in December 2025 to 6market its biosimilar of the cancer drug pegfilgrastim.

"Pegfilgrastim is set to enter the United States (US) market, while ophthalmic drug Ranibizumab is lined up for launches across the US, Europe and Japan.

Beyond pegfilgrastim and ranibizumab, Lupin plans to bring biosimilars of the cancer drugs nivolumab, dinutuzumab and pertuzumab to India. The company already markets a biosimilar of the autoimmune condition drug etanercept in Europe and Japan through partnerships.

Source: MedPath




Charles Joynson, WaveData MD, asks 'Promethazine Hydrochloride Tabs 10mg 56, is the price on the rise again?'

Market prices for this product were very stable between launch in November 2014 and the beginning of 2022 when they started to increase rapidly. What followed was an extreme price increase with prices rising from below £3.00 to above £25.00. This extreme rise may reflect a demand increase due to increased prescribing for sleep and anxiety related problems in the wake of the Covid pandemic.

This led to a situation where it was challenging to find stock at a reasonable prices, with any spare boxes available being soaked up by the increasing prescribing. Concessions were granted twice in 2022, three times in 2023 and twice in 2024.

This means the outcome of the demand change was a profitability crisis. However, by the beginning of 2025 prices had returned to normal levels and fell even lower to below £2.00. Prices are rising again now which may be the result of a combination of continued demand increases and with prices below £2.00, a profitability challenge. The current market prices are likely to be just too low to keep this product profitable, and with the drug tariff £1.79, we may see the initiation of a series of price bounces.

Promethazine Hydrochloride Tabs 10mg 56 Long Term Pricing



Boehringer launches hub for patient experience data

Biopharmaceutical company Boehringer Ingelheim has launched PED Essentials, a comprehensive, freely available e-learning hub designed to help patient organisations capture, analyse, and effectively communicate Patient Experience Data (PED).

PED – which Boehringer describes as "direct insights that patients provide on their symptoms, quality of life, treatment preferences, and unmet needs" – is also becoming a focal point for regulators, including the EMA, which is currently looking into how it could be incorporated into medicine development programmes and marketing authorisation applications.

Helping patients generate PED could catalyse a new chapter in healthcare innovation," according to Lykke Hinsch Gylvin, Boehringer's chief medical officer and head of global medicine.

Source: Pharmaphorum



UK and Singapore launch negotiations for new agreement

On 22 September 2026, the UK and Singapore officially launched negotiations for a new Mutual Recognition Agreement (MRA) on pharmaceutical Good Manufacturing Practice (GMP).

Pharmaceuticals are an important component of the expanding UK-Singapore trade relationship. Goods trade between the UK and Singapore was worth £12bn in 2025, a 24% increase from 2024. The MRA will cut costs for UK-Singapore medicines trade and build on existing UK-Singapore trade worth over £300 million in 2025, bringing particular benefits to the South East of England, East of England, and Wales.

Source: GOV UK



Top Ten Branded Product Searches: WaveData Live

These are the most commonly investigated Branded products on WaveData Live in the last 35 days. Both UK and PI prices were viewed, average prices are shown.

Product	Jun-26	Jul-26	Aug-26	Sep-26
Invokana Tabs 100mg 30	£27.61	£25.23	£25.23	£27.31
Nasonex Nasal Spray 50mcg 1 (140 Doses)	£5.43	£5.21	£4.98	£4.91
Avamys Nasal Spray 1 (120 Doses)	£5.99	£5.88	£5.86	£5.80
Trusopt Eye Drops Pres Free 2% 0.2ml x 60	£23.65	£23.45	£23.35	£22.91
Briviact Oral Solution 10mg/ml 300ml	£114.50	£113.46	£113.65	£113.43
Briviact Tabs 100mg 56	£112.10	£107.13	£114.04	£105.27
Briviact Tabs 25mg 56	£121.57	£115.09	£114.51	£111.80
Elocon Cream 0.1% 100g	£9.95	£9.80	£9.35	£9.32
Trimbow Nexthaler Inhalation Powder 88mcg/5mcg/9mcg 1 (120 Doses)	£43.98	£44.39	£44.39	£44.39
Abilify Maintena Vial 400mg 1	£200.07	£212.25	£212.67	£211.19

Prices correct at time of compilation, but may be subject to change.



Top Ten Generic Product Searches: WaveData Live

These are the most commonly investigated Generic products on WaveData Live in the last 35 days. Both UK and PI prices were viewed, average prices are shown.

Product	Jun-26	Jul-26	Aug-26	Sep-26
Omeprazole Caps 20mg 28	£0.38	£0.38	£0.35	£0.37
Dapagliflozin Tabs 10mg 28	£2.91	£2.36	£2.18	£2.90
Zopiclone Tabs 7.5mg 28	£0.58	£0.60	£0.58	£0.62
Atorvastatin Tabs 20mg 28	£0.39	£0.37	£0.34	£0.41
Zopiclone Tabs 3.75mg 28	£0.55	£0.57	£0.57	£0.58
Metformin Tabs 500mg 28	£0.27	£0.24	£0.26	£0.23
Lansoprazole Caps 15mg 28	£0.43	£0.44	£0.51	£0.56
Apixaban Tabs 5mg 56	£2.59	£2.05	£1.37	£1.60
Sertraline Tabs 100mg 28	£0.84	£0.70	£0.66	£0.68
Famotidine Tabs 20mg 28	£0.82	£0.80	£0.71	£0.73

Prices correct at time of compilation, but may be subject to change.



FUTURE INDUSTRY EVENTS

Delivering patient benefit from innovation and health tech	2nd Oct 26	Online
Next steps for improving patient access to innovative medicines and health technologies	2nd Oct 26	Online
BioTechX	6th - 8th Oct 26	Basel
BioUK South West Showcase & Science Social	14th Oct 26	Bristol
2nd MedTech Meets AI	14th & 15th Oct 26	Barcelona
Next steps for professional healthcare regulation in the UK	22nd Oct 26	Online
Next steps for medicine regulation in the UK	23rd Oct 26	Online
The 5th European Congress on Controversies in LEUKEMIA	26th - 27th Oct 26	Germany
World Orphan Drug Congress Europe 2026	26th - 28th Oct 26	Amsterdam
Supply Chain Excellence Awards	5th Nov 26	London
The 3rd European Congress on Dermato-Oncology2026	12th - 13th Nov 26	Netherlands
Future for vaccines in the UK	24th Nov 26	Online
Next steps for NICE in England	30th Nov 26	Online
Health Expo Cyprus	5th - 6th Dec 26	Limassol
Next steps for clinical research and trials in the UK	15th Dec 26	Online
AI in Healthcare Conference	23rd Feb 27	Manchester
World EPA Congress 2027	2nd & 3rd Mar 27	Amsterdam
The 9th Int'l Congress on Controversies in Fibromyalgia	13th - 14th Apr 27	Greece
PharmaVenue 2027	26th - 27th Apr 27	Barcelona
LogiPharma	25th - 27th May 27	Vienna

WaveData's Bulletin is a free-of-charge monthly service. Please let us know if you would like an article considered for inclusion, or if you have any colleagues who would like to be added to our subscribers list. You can view previous editions of The Bulletin in the [WaveData Knowledge Base](#).

If you need any assistance, or would like to find out more about our pricing or prescription services please get in touch.

Our Services:

- [WaveData Live](#): UK & EI Pharma Pricing 1-35 days
- [WaveData Pharma TouchStone](#): UK & EI Pharma Pricing up to 6 months
- [WaveData BPPI](#): UK Pharma Pricing up to 10 years
- [WaveData ScriptMap](#): GP Prescribing Data updated monthly

Editor: Jackie Moss

Contact: bulletin@wavedata.co.uk

